The effectiveness of combination of rituximab–cyclophosphamide–dexamethasone in the treatment of Waldenstrom’s macroglobulinemia despite of the failure of several earlier lines of treatment

Abstract

A 45-year-old man presented with diagnosis of Waldenstrom’s macroglobulinemia, International Prognostic Scoring System for Waldenström’s macroglobulinemia intermediate, is described. Between 2005 and 2008 he was treated with chlorambucil and prednisone then with fludarabine, and later with cyclofosfamid–vincristine–prednisone regimens but only temporary stabilization of disease was achieved. In 2008 the dynamic, histologically confirmed progression of the disease was observed. The high tumor burden and aggressive clinical features prompted the initiation of rituximab–dexamethasone–cyclophosphamide (RDC) therapy. The treatment course was uneventful and without toxicity. Following 6 courses of RDC a complete response (CR) was achieved in January 2009 and the patient remains in CR so far.
Hematologia 2011; 2, 2: 209–213